FDA Approves GSK’s HIBSAGO; Phase 3 Data Show 19% Functional Cure Rate
Ionis Pharmaceuticals said its partner GSK received U.S. FDA approval for HIBSAGO (bepirovirsen). The Phase 3 B-Well trials showed a 19% functional cure rate.
Ionis Pharmaceuticals announced its partner GSK received U.S. FDA approval for HIBSAGO (bepirovirsen) showing a 19% functional cure rate in Phase 3 B-Well trials.Key Highlights:Original SEC Filing: IONIS PHARMACEUTICALS INC [ IONS ] - 8-K - Oct. 21, 2026This is an AI-powered summary. It may contain…